



(12) Translation of
European patent specification

(11) NO/EP 3056485 B1

NORWAY

(19) NO
(51) Int Cl.
C07D 231/12 (2006.01)

Norwegian Industrial Property Office

(21)	Translation Published	2018.10.01
(80)	Date of The European Patent Office Publication of the Granted Patent	2018.05.09
(86)	European Application Nr.	16157716.8
(86)	European Filing Date	2010.10.27
(87)	The European Application's Publication Date	2016.08.17
(30)	Priority	2009.10.27, US, 255159 P
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
	Designated Extension States:	BA, ME
(73)	Proprietor	Orion Corporation, Orionintie 1, 02200 Espoo, FI-Finland
(72)	Inventor	WOHLFAHRT, Gerd, Vattuniemenkatu 14 C 35, FI-00210 Helsinki, FI-Finland TÖRMÄKANGAS, Olli, Rossinpolku 2 D 4, FI-20380 Turku, FI-Finland KARJALAINEN, Arja, Iltatie 4 B 6, FI-02210 Espoo, FI-Finland KNUUTTILA, Pia, Väinämöisenkatu 5, FI-20660 Littoinen, FI-Finland HOLM, Patrik, Nilsbynkaari 77, FI-21630 Lielähti TL, FI-Finland RASKU, Sirpa, Kavaljeerintie 14 B 10, FI-01520 Vantaa, FI-Finland VESALAINEN, Anniina, Kohmontie 10 A 26, FI-20540 Turku, FI-Finland SALO, Harri, Puolikontie 6 C, FI-20300 Turku, FI-Finland HÖGLUND, Iisa, Kaniikintie 17, FI-20300 Turku, FI-Finland
(74)	Agent or Attorney	ZACCO NORWAY AS, Postboks 2003 Vikå, 0125 OSLO, Norge

(54)	Title	ANDROGEN RECEPTOR MODULATING COMPOUNDS
(56)	References Cited:	WO-A2-2008/124000, NARAYANAN RAMESH ET AL: "Selective androgen receptor modulators in preclinical and clinical development.", NUCLEAR RECEPTOR SIGNALING, vol. 6, no. E010, 2008, pages 1-26, XP002623904, ISSN: 1550-7629


Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

1

PATENTKRAV**1. Forbindelse**

med

formel



2. Forbindelse ifølge krav 1, som er 2-klor-4-(1H-pyrazol-5-yl)benzonitril.

- 5 **3. Forbindelse** ifølge krav 1, som er (S)-4-(1-(2-aminopropyl)-1H-pyrazol-3-yl)-2-klorbenzonitril.